NORCROSS, Ga.--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB: ARGA) or “Auriga”, a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and Xerostomia, announced today that it has entered into a trade development agreement, under which New Pharmaceutical Strategies (NPS, a division of VCG & Associates), will develop trade development strategies and initiatives focused on enhancing sales of Auriga’s product line. Under the two-year agreement, NPS will focus on enhancing sales of Auriga’s products by expanding its position in the retail and drug wholesale marketplace.
